Previous 10 | Next 10 |
Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year tests of the top three forensic algorithms used to detect bankruptcy risk, earnings manipulation, and financial irregularities. My forward testing compiles portfolio...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Agilent (NYSE: A ) initiated with Buy rating and $92 (14% upside) price target at UBS. More news on: Agilent Technologies, Inc., Amgen Inc., Fluidigm Corporation, Healthcare stocks news, Stocks on the move, , Read more ...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced the closing of its research collaboration and license agreement with Genentech...
Xencor, Inc. (XNCR) Q4 2018 Results Earnings Conference Call February 25, 2019, 04:30 PM ET Company Participants Charles Liles - Associate Director and Head of Corporate Communications and IR Bassil Dahiyat - President and CEO Paul Foster - SVP and Chief Medical Officer John Ku...
Xencor (NASDAQ: XNCR ) Q4 results ($M): Revenues: 11.6 (-61.6%). Drop due to milestone payments from Alexion last year. More news on: Xencor, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Xencor (NASDAQ: XNCR ): Q4 GAAP EPS of -$0.32 beats by $0.17 . More news on: Xencor, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
MONROVIA, Calif. , Feb. 25, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today reported financial results for ...
Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Neutral rating and $135 (6% upside) price target at Guggenheim. More news on: Alexion Pharmaceuticals, Inc., Dermira, Exelixis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
MONROVIA, Calif. , Feb. 20, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that the U.S. Food and ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-05 16:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through ...
2024-06-04 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...